Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials

Recruiting at 7 trial locations

Overseen By Associate Director, Clinical Operations

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Ascidian Therapeutics, Inc

Disqualifiers: Other gene mutations, Retinal disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

50 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Who Is on the Research Team?

Alia Rashid

Principal Investigator

Ascidian Therapeutics

Are You a Good Fit for This Trial?

Inclusion Criteria

I have a mutation in the ABCA4 gene.

I have been diagnosed with Stargardt disease or cone-rod dystrophy.

Timeline for a Trial Participant

Prescreening

The prescreening study consists of genetic and visual assessments to determine research eligibility for ACDN-01 clinical trials

12 months

At least 1 onsite visit

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 years

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

Group I: Prescreening Group Experimental Treatment 1 Intervention

The prescreening study consists of genetic and visual assessments and will require at least 1 onsite visit. All clinical assessments performed are for the purpose of determining research eligibility for ACDN-01 clinical trials.

Who Is Running the Clinical Trial?

Ascidian Therapeutics, Inc

Lead Sponsor

Trials

2

Recruited

60+